Ono Pharmaceutical Co. Ltd. has entered an option and research collaboration agreement with Monash University to discover and develop antibodies targeting G protein-coupled receptors (GPCRs) with the aim of creating novel therapeutics for the treatment of autoimmune and inflammatory diseases.